Library

CHPJ Library

Articles

State importation programs are unrealistic: diverting prescription drugs to American consumers would rapidly deplete the Canadian drug supply

Brett J Skinner, PhD | CHPI | 2024

Les programmes d’importation des États-Unis sont irréalistes : détourner les médicaments d’ordonnance vers les consommateurs américains épuiserait rapidement l’approvisionnement en médicaments au Canada

Brett J Skinner, PhD | CHPI | 2024

Government development of ‘made-in-Canada’ CAR-T cell immunotherapies: assessing cost, risk, access, and alternatives

Brett J Skinner, PhD | CHPI | 2024

Identifying Spasticity Treatment Gaps in Long-term Care and Community Settings from Ontario Real-world Evidence

Omar D. Khan, MD, FRCPC; Cathy Vo, PharmD; Huijuan Yang, Shoghag Khoudigian-Sinani; Bradley Millson, MBS; Riccardo Pedersini, PhD; Galit Kleiner, MD, FRCPC | Hotel Dieu Shaver Health and Rehabilitation Centre, Allergan, an AbbVie Company, IQVIA Solutions Canada Inc., Noesis Healthcare Technologies, Baycrest Health Sciences | 2024

Community Trust and Public Health Compliance: COVID-19 Experiences in Newfoundland and Labrador

Thaneswary Rajanderan PhD, Rodney Russell PhD, Chand S Mangat PhD, Douglas Howse BSc, Cheryl PZ Foo MD, Atanu Sarkar PhD | Memorial University NL, Infectious Diseases Research Centre Winnipeg, Government of Newfoundland and Labrador | 2024

Benefit of expedited regulatory approval for oncology drugs eliminated by slow reimbursement reviews and price negotiations

Nigel S B Rawson PhD, David J Stewart MD | University of Ottawa, Ottawa Hospital | 2024

Exploring the Ethics of Paediatric Surgical Prioritization in Canada: A Survey of Existing Institutional Guidance

Kayla Wiebe MA PhD candidate, Randi Zlotnik Shaul PhD, Simon Kelley MBChB PhD, Roxanne Kirsch MD | The Hospital for Sick Children | 2024

Effects of the COVID-19 pandemic on the number and characteristics of public drug program beneficiaries in Ontario, Canada

Z Bouck PhD, D McCormack MSc, M Tadrous PhD, J M Paterson MSc, T Campbell MPH, T Gomes PhD | St. Michael’s Hospital, University of Toronto, McMaster University | 2024

A Growing Problem: Is Canada’s Healthcare System Keeping Up with Newcomers?

Lauren Eastman BMSc MD CCFP; Sukhy K. Mahl MBA; Shoo K. Lee MBBS FRCPC PhD DHC OC | University of Alberta; University of Toronto; Mount Sinai Hospital | 2024

A Canadian Healthcare Policy Framework for Clinical Care at the End and the Beginning of Life: Prioritization, Human Resource Management, and Remuneration Models

R Douglas Wilson MD MSc FRCSC | University of Calgary | 2024

Public v private insurance coverage for new drugs in Canada, 2018-2023, 7th Edition

CHPI Research | 2024

Waiting for new medicines in Canada, Europe, and the United States 2018-2023

CHPI Research | 2024

Patented Medicines Expenditure in Canada 1990–2022 8TH Edition

CHPI Research | 2024

Alberta’s research priorities to advance organ donation and transplantation: an ecosystem-based and consensus-driven approach to strategic research planning.

Saeideh Davoodi, PhD et al | University of Alberta | 2024

Physician Pay Inequity: Time to Act?

Lauren Eastman, BMSc, MD, CCFP; Sukhy K. Mahl, MBA; Shoo K. Lee, MBBS, FRCPC, PhD, DHC, OC | University of Alberta; University of Toronto; Mount Sinai Hospital | 2023

Canadian public payer best practices for providing timely patient access to cancer therapies

Judith Glennie BScPhm MSc PharmD; Kathleen Gesy; Yen Nguyen BPharm | 2023

Adapting the Safe Consumption Site Model for Patient-Procured MDMA

Shannon Dames RN MPH EdD; Crosbie Watler MD; Kerrie Miller RN; Robert W.E. Laurie LLB; Vivian W.L. Tsang MD; Raimey Olthuis PhD; Pearl Allard RN; Elena Argento PhD; Pam Kryskow MD | 2023

The Supply of Primary Care Physicians in Alberta 2018-2022 – A Dire Description

Terrence McDonald, MD, MSc; Jessie Hart Szostakiwskyj, MSc; Lee A. Green, MD, MPH | University of Calgary; University of Alberta | 2023

Toward a Policy Framework to Improve the Health Care of Homeless Individuals

Kirk A Collins, PhD | Trent University | 2023

Evaluation of the PMPRB regulatory performance on price review for new patented drugs in Canada, 2008-2021

Nigel S B Rawson, PhD; Brett J Skinner, PhD | Canadian Health Policy Institute | 2023

Herceptin® treatments in hospital and at CLSCs for breast cancer patients in Quebec: comparative analysis of costs and care trajectories.

Gerald Batist, MD; Geneviève Faucher, MD; Sonia Joannette, RN; Yanick Labrie, MA; Giovanna Speranza, MD | 2023

Traitements d’Herceptin© à l’hôpital et en CLSC pour les patientes atteintes de cancer du sein au Québec: analyse comparative des coûts et des trajectoires de soins.

Gerald Batist, MD; Geneviève Faucher, MD; Sonia Joannette, RN; Yanick Labrie, MA; Giovanna Speranza, MD | 2023

New cancer drugs in Canada 2012 to 2021: an economic analysis of cost, benefit, availability, and public insurance coverage.

Brett Skinner PhD | Canadian Health Policy Institute | 2023

Economic burden of cardiomyopathy in Canada 2018 to 2021: opportunity for cost avoidance through pharmaceutical innovation.

Brett Skinner PhD | Canadian Health Policy Institute | 2023

Policy approaches for increasing participation with personal health information and data sharing (HIDS)

Daniel J. Caron PhD; Vincent Nicolini, PhD; Alexandre Prud’homme | École nationale d'administration publique (ENAP); Carleton University; Université de Montréal | MAR 2023

An Evaluation of Access and Policy Initiatives for Breast Cancer Screening in Ontario

Michael J. E. Smith, RN, BScN, MN; Erin Heynemans, RN, BScN, MN(c); Deanne Drover, MCISc, BSc, BEd, BN, RN; Ashley Lagleva, RN, BScN; Paige Lau, BSc, MCISc, MRT(T); Mary Ndu, MPH, PhD (ABD) | Western University | FEB 2023

Toward a Policy Framework for Sustainable Rural Obstetrics and Surgical Care in Canada

R Douglas Wilson MD MSc FRCSC, Professor Emeritus | University of Calgary, Alberta Health Services | FEB 2023

Canada falls behind in new drug submissions compared with the United States and Europe

Nigel Rawson PhD | Canadian Health Policy Institute | 17 JAN 2023

QALYs and Value Assessment

Mayvis Rebeira PhD | Canadian Health Policy Institute | 24 NOV 2022

Healthcare’s search for “wellness”: How bioethics reduces burnout among health professionals

Carey DeMichelis PhD; Randi Zlotnik Shaul JD LLM PhD; Roxanne Kirsch MD MBE | University of the Fraser Valley; The Hospital for Sick Children; University of Toronto | SEP 2022

Projected Ontario budget savings from reduced long-term care utilization due to a disease-modifying Alzheimer’s treatment

Hankyung Jun PhD; Zehao Shi; Soeren Mattke MD, DSc | University of Southern California | SEP 2022

Integration within Long-Term Care: A Comparative Analysis of Nova Scotia and British Columbia

Apurva Dixit BHSc, Praniya Elangainesan BSc, Dr. Abi Sriharan PhD MSc | University of Toronto Faculty of Medicine, Institute of Health Policy, Management and Evaluation | JUL 2022

Effect of amended Patented Medicine Regulations on industry decisions to launch new drugs in Canada

Nigel S B Rawson PhD, Courtney Abunassar MPA, Donna Lawrence MSc | CHPI, PDCI Market Access | JUL 2022

Opportunities to improve health care processes and services outcomes in Canada

R Douglas Wilson MD MSc FRCSC, Professor Emeritus | University of Calgary, Alberta Health Services | JUL 2022

Patented Medicines Expenditure in Canada 1990–2020 7th Edition

CHPI Research | JUN 2022

Patent term erosion and the availability of new medicines in Canada 2000-2022

CHPI Research | MAY 2022

Liability issues for the use of artificial intelligence (AI) in health care as a home assistance tool

Mélanie Bourassa Forcier, LL.L., LL.B., M.Sc., D.C.L.; Lara Khoury Ad.E., LL.B., BCL, DPhil; Nathalie Vézina B.C.L., LL.B., D.E.A. | University of Sherbrooke, McGill University | APR 2022

Waiting for new medicines in Canada, Europe and the United States 2016-2021

CHPI Research | APR 2022

Access to new medicines in Canada 2016-2021: Federal-provincial public drug programs and private sector drug plans

CHPI Research | APR 2022

The PMPRB: Where Are We Now and What’s Next?

Dara Jospé, JD/LLB and Mathieu Gagné LLD | Fasken Martineau DuMoulin S.E.N.C.R.L., s.r.l. | MAR 2022

Bringing value to healthcare through ambulatory services

Adam Saporta, PT, BSc, MScPT, CHE et al | Sunnybrook Health Sciences Center | MAR 2022

Analysis of interventions addressing the nutrition status of seniors in Ontario

Lauren McKay MPH et al | The Gathering Food Centre, North Bay Parry Sound District Health Unit, Region of Waterloo, Western University | FEB 2022

A Dollar a Day May Keep the Doctor Away: Putting Spending on Food and Healthcare on a Scale

Katerina Maximova PhD et al | University of Toronto, University of Alberta | FEB 2022

Pharmacy scope of practice and access to Opioid Agonist Therapies (OAT) in Canada after COVID-19

Sarah Lussier-Hoskyn MA Economics, Brett Skinner PhD | Canadian Health Policy Institute | JAN 2022

Champ d’exercice de la pharmacie et accès aux traitements par agonistes opioïdes (TAO) au Canada après la COVID-19

Sarah Lussier-Hoskyn MA Economics, Brett Skinner PhD | Canadian Health Policy Institute | JAN 2022

Why would Canada have the longest wait times for an Alzheimer’s treatment among the G7 countries?

Soeren Mattke MD DSc, Mo Wang MS | University of Southern California | JAN 2022

Rogue Regulator: PMPRB’s false narrative is driving dangerous drug price controls

Brett Skinner PhD | Canadian Health Policy Institute | DEC 2021

Availability and Accessibility of Essential Drugs for Rare Disorders in Canada

Nigel Rawson PhD | Canadian Health Policy Institute | OCT 2021

Canada’s COVID-19 Vaccine Procurement Strategy: Comparisons with the United Kingdom and Israel

Mayvis Rebeira PhD | Canadian Health Policy Institute | SEP 2021

Prix des médicaments brevetés au Canada et dans 13 autres pays

Brett Skinner PhD | Canadian Health Policy Institute | SEP 2021

Prices for Patented Medicines in Canada and 13 Other Countries

Brett Skinner PhD | Canadian Health Policy Institute | AUG 2021

Home-Based Management of Chronic Diseases

Lesly Deuchar MN, Michael Stickland PhD et al | Alberta Health Services and University of Alberta | AUG 2021

Community Characteristics and MAiD Uptake in Ontario

Michaela Kelly MSc, Ellen Wiebe MD | University of British Columbia | AUG 2021

Oversight of Medical Assistance in Dying (MAiD) in Canada

Ellen Wiebe MD et al | University of British Columbia | AUG 2021

A Novel Emergency Operating Room Scheduling Software Promotes Efficiency and Cost-Effectiveness

James Lee MD et al | McGill University Health Centre | AUG 2021

Development of the Patient and Public Involvement Questionnaire for Canadian Formulary Committees

Lee Verweel PhD et al | Ryerson University | JUL 2021

Death Denied or Death Delayed? Outcomes among Nova Scotia patients deemed ineligible for MAiD

Caitlin Lees MD MA MSc et al | Queen Elizabeth II Health Sciences Center, Dalhousie University, Halifax; Nova Scotia Health Authority | JUL 2021

Harassment Reporting Mechanisms for Physicians and Medical Trainees in Alberta

Kendra Martel et al | Cumming School of Medicine, University of Calgary; Division of Neurology, University of Alberta; Alberta Health Services | JUL 2021

Advance Requests for MAiD in Dementia: Survey of Canadian Public and MAiD Practitioners

Adrian Byram PhD, Peter Reiner PhD et al | University of British Columbia | JUN 2021

Patented Medicines Expenditure in Canada 1990-2019

CHPI Annual Research | JUN 2021

Modernizing Canadian Pharmacists’ Scope of Practice for Controlled Drugs and Substances

Zahava R.S. Rosenberg-Yunger PhD MA et al | Ted Rogers School of Management, Health Services Management, Ryerson University; School of Pharmacy, Memorial University of Newfoundland; Neighborhood Pharmacy Association of Canada | JUN 2021

Essais cliniques au Canada: signes inquiétants persistent malgré la réponse superficielle du CEPMB

Nigel Rawson PhD | Canadian Health Policy Institute | APR 2021

Clinical Trials in Canada: Worrying Signs Remain Despite PMPRB’s Superficial Response

Nigel Rawson PhD | Canadian Health Policy Institute | MAR 2021

National Strategy for Drugs for Rare Diseases should Prioritize Patients not Cost Containment

Nigel S B Rawson, PhD and John Adams, BA | Canadian Health Policy Institute; Best Medicines Coalition | MAR 2021

Health Technology Assessment Standards and Practices: How Does Canada Compare with Other Countries?

Nigel S B Rawson, PhD, Canadian Health Policy Institute | FEB 2021

Clinical Trials in Canada: Worrying Signs that PMPRB Changes will Impact Research Investment

Nigel S B Rawson, PhD | Canadian Health Policy Institute | FEB 2021

Essais cliniques au Canada: des signes inquiétants que l’incertitude liée aux changements du CEPMB affectera les investissements en recherche

Nigel S B Rawson, PhD | Canadian Health Policy Institute | FEB 2021

Patented Medicines Expenditure in Canada 1990-2018

CHPI Research | DEC 2020

Canada’s Vaccine Development Capacity and the Federal Government’s Management of COVID-19

Paul Lucas, Retired President and CEO | GlaxoSmithKline | DEC 2020

E-Mental Health Services and Unmet Needs of Canadians

Mark Embrett, PhD | Dalhousie University; Nova Scotia Health | OCT 2020

Universal public funding for dental care in Canada: problems, policies, and politics.

Homam Albaghdadi DDS, MSCH(HPE), MSc, BSc(Hons) | Mount Sinai Hospital; Women's College Hospital; University Health Network; University of Toronto | OCT 2020

Ensuring early access to a COVID-19 vaccine in Canada

Brett Skinner PhD | Canadian Health Policy Institute | OCT 2020

Vaccines policy in Canada: International and Domestic Comparisons.

Brett Skinner PhD | Canadian Health Policy Institute | OCT 2020

Career Options and Professional Integration of Internationally Trained Physicians in Canada.

Sanjida Newaz, MBBS, MSc | Saskatchewan Health Authority | OCT 2020

Evidence that regulating pharmaceutical prices negatively affects R&D and access to new medicines.

Yanick Labrie, MSc | Canadian Health Policy Institute | JUN 2020

COVID-19 Economic Costs and the Implicit Value of a Life-Year in Canada

Brett Skinner PhD | Canadian Health Policy Institute | JUN 2020

Did the PMPRB censor CHPI’s Submission to its Draft Guidelines Consultation?

CHPI Research | APR 2020

Clinical Trials in Canada Decrease: A Sign of Uncertainty Regarding Changes to the PMPRB?

Nigel S B Rawson, PhD | Canadian Health Policy Institute | APR 2020

A Socio-Psychological Perspective on Flattening the COVID-19 Curve.

Umar Ruhi, PhD, MBA, CIPS-ISP | University of Ottawa | APR 2020

Patented Medicines Costs of Private Insurers: PMPRB Implications.

Brett Skinner PhD | Canadian Health Policy Institute | MAR 2020

Fewer new drug approvals in Canada: early indication of unintended consequences from new PMPRB regs?

Nigel S B Rawson, PhD | Canadian Health Policy Institute | MAR 2020

New Patented Medicine Regulations in Canada: Updated Case Study. (EN/FR)

Nigel SB Rawson, PhD, Donna Lawrence, MSc | CHPI | JAN 2020

Nouvelle réglementation sur les médicaments brevetés au Canada: Étude de cas mise à jour.

Nigel S B Rawson, PhD and Donna Lawrence, MSc | CHPI | JAN 2020

New drug submissions in the United States and Canada 2014-2019: trends and policy implications.

Pete Ecclestone | OCT 2019

The costs of Immunoglobulin treatment in hospital and in the home in Quebec

Yanick Labrie, MSc | Canadian Health Policy Institute | SEP 2019

New pathways for U.S. importation threaten Canadian prescription drug supply

Marv Shepherd, PhD | University of Texas at Austin | SEP 2019

Preventive care of the future? Economic analysis of cardiovascular risk management.

Yanick Labrie, M.Sc. | SEP 2019

Coverage of new medicines in Federal-Provincial public drug plans in Canada 2009-2018

CHPI Research | SEP 2019

Coverage of new medicines in private versus public drug plans in Canada 2009-2018

CHPI Research | SEP 2019

Potential impact of U.S. demand on the Canadian supply of 46 prescription drugs.

Brett Skinner PhD | Canadian Health Policy Institute | SEP 2019

Clinical Duty to Recontact in Genetic Testing: Insights from the Safety-Related Duty to Recall

Meaghan Storey, BSc and Randi Zlotnik Shaul, JD, LLM, PhD et al | McGill University, University of Wisconsin, The Hospital for Sick Children, University of Toronto | AUG 2019

Patented drug prices and clinical trials in 31 OECD countries 2017: implications for Canada’s PMPRB.

Brett Skinner PhD | Canadian Health Policy Institute | AUG 2019

HTA and public coverage of new mental health drugs in Quebec and Canada.

CHPI Research | JUL 2019

Medical resources and spending across provincial healthcare systems in Canada.

CHPI Research | JUL 2019

Medical Resources in Canada and OECD countries. 2019 Edition.

CHPI Research | MAY 2019

Close the Gaps: Patient Benefits and Taxpayer Costs of 3 Pharmacare Options

Brett Skinner PhD | Canadian Health Policy Institute | APR 2019

Evidence that innovative medicines improve health and economic outcomes: focused literature review.

CHPI Research | APR 2019

Pan-Canadian Pharmaceutical Alliance negotiations 2014-2018

Nigel S B Rawson, PhD | Canadian Health Policy Institute | MAR 2019

Out-of-pocket prescription drug costs: What are the implications for National Pharmacare?

CHPI Research | OCT 2018

Taxpayer Cost of National Pharmacare: Disputing the Parliamentary Budget Officer’s Estimate

CHPI Research | OCT 2018

Coverage of new medicines in Federal-Provincial public drug plans in Canada 2008-2017

CHPI Research | 2018

Coverage of new medicines in public versus private drug plans in Canada 2008-2017

CHPI Research | 2018

New Patented Medicine Regulations in Canada: Case Study of a Manufacturer’s Decision-Making

Nigel S B Rawson, PhD | Canadian Health Policy Institute | 2018

Prescription drug plan coverage 2016: how many Canadians were insured, under-insured or uninsured?

Brett Skinner PhD | Canadian Health Policy Institute | JUN 2018

Comparing expert representation on HTA advisory committees in Canada, the UK and Australia

Brett Skinner PhD | Canadian Health Policy Institute | 2018

Facts about the cost of patented drugs in Canada: 2018 Edition.

CHPI Research | 2018

Consequences of over-regulating the prices of new drugs in Canada

Brett Skinner PhD | Canadian Health Policy Institute | MAR 2018

Medical devices spending in Canada 2013-2017

CHPI Research | 2018

Does Canada need a Patented Medicine Prices Review Board?

Brett Skinner PhD | Canadian Health Policy Institute | 2017

Societal cost savings from abuse deterrent formulations for prescription opioids in Canada

Brett Skinner PhD | Canadian Health Policy Institute | 2017

HTA decisions and access to mental health treatments in Canada’s public drug plans

Kimberley Tran (M.A.), Nigel SB Rawson (Ph.D.), Brett J Skinner (Ph.D.) | CHPI | 2017

The fiscal burden of provincial government health spending across Canada

CHPI Research | 2017

Hospital spending across Canada’s Provinces, 1990-2014

CHPI Research | 2017

Costs without benefits for patients? Non-medical spending in Canada’s public health system

CHPI Research | 2017

Les gouvernements pourraient économiser 5 milliards de dollars par année